|
| |
sanofi-aventisSanofi-aventis is the world’s 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines.
| Contact Details: |
| 300 Somerset Corporate Bld |
| Bridgewater |
| New Jersey |
| 08807-2854 |
| United States of America |
| Tel: | 800-981-2491 |
| Fax: | |
| Email: | |
| WWW: | www.sanofi-aventis.us/
|
|
Loading...
|
Recent Publications by sanofi-aventis: |  |
No replication of genetic association between candidate polymorphisms and Alzheimer's disease.
Alzheimer's disease is a genetically complex disorder, for which new... | 6th November, 2009
| Biological Sciences Department, sanofi-aventis Recherche et Developpement,
| Neurobiol Aging. 2009 Nov 2.
DOI Direct Link |
A robust assay measuring GLUT4 translocation in rat myoblasts overexpressing GLUT4-myc and AS160_v2.
Muscle and fat cells translocate GLUT4 (glucose transporter 4) to the... | 27th October, 2009
| Sanofi-Aventis Deutschland, 65926 Frankfurt am Main, Germany.
| Anal Biochem. 2009 Oct 23.
DOI Direct Link |
Discovery of covalent inhibitors for MIF tautomerase via cocrystal structures with phantom hits from virtual screening.
Biochemical and X-ray crystallographic studies confirmed that... | 20th October, 2009
| Discovery Research, sanofi-aventis, Bridgewater, NJ 08807, USA.
| Bioorg Med Chem Lett. 2009 Dec 1;19(23):6717-20. Epub 2009 Oct 1.
DOI Direct Link |
Antihypertensive drug therapy and blood pressure control in men and women: an international perspective.
Cardiovascular death represents the single largest cause of mortality in... | 3rd October, 2009
| [1] Medical Faculty Carl Gustav Carus, Institute for Clinical
| J Hum Hypertens. 2009 Oct 1.
DOI Direct Link |
Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
Recently, a contaminant was found in some clinically used unfractionated... | 2nd October, 2009
| sanofi-aventis, 13 Quai Jules Guesde, Vitry sur Seine, France.
| Clin Appl Thromb Hemost. 2009 Jul-Aug;15(4):395-401. Epub 2009 Jul 17.
DOI Direct Link |
→View more sanofi-aventis research publications. |
Press Releases on sanofi-aventis:
|
 |
| New GoMeals(TM) iPhone Application from sanofi-aventis U.S. to Help People with Diabetes Eat Healthy Anywhere, Anytime |
19th November, 2009 |
sanofi-aventis U.S. |
BRIDGEWATER, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that GoMeals(TM), a new iPhone application (app) designed to help people living with diabetes make healthy food
|
| Saatchi & Saatchi Wellness Wins Grand Clio and Gold Clio |
17th November, 2009 |
Saatchi & Saatchi Wellness |
NEW YORK, Nov. 17 /PRNewswire/ -- Saatchi & Saatchi Wellness took home the Grand Clio Award and won one of only two Gold Clio Healthcare awards handed out on Friday, November 13th at the inaugural
|
| Sanofi-aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation |
16th November, 2009 |
|
PARIS, November 16 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today
the launch of the RealiseAF registry (Real Life global Survey Evaluating
patients with Atrial
|
| First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes |
15th November, 2009 |
|
ORLANDO, Florida, November 15 /PRNewswire/ -- Results from the RecordAF registry (REgistry on Cardiac rhythm
disORDers assessing the control of Atrial Fibrillation), presented today at
the Scientific
|
| Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media |
12th November, 2009 |
Euro RSCG Worldwide |
-- Even when it was not the direct catalyst for doctor-patient dialogue,
two-thirds of all surveyed stated they found social media a helpful
source of health information when they
|
sanofi-aventis Patents: |  |
| US Patent No. | Title |
| 7531569 | Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives
|
| 7553845 | Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives
|
| 7550582 | Polyamide nucleic acid derivatives and agents, and processes for preparing them
|
| 7550257 | Process for identifying substances which modulate the activity of hyperpolarization-activated cation channels
|
| 7547706 | 1H-pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use
| →View more sanofi-aventis patents. |
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 39 individuals from sanofi-aventis using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 688 times since April 2007, the link to the organisation's website has been followed 63 times Recent Search Terms used to find this page: Sanofi-aventis presents global survey on patients with AF | sanofi aventi | sanofi aventis R D nov 2009 | MIF Aventis Sanofi | sanofi frankfurt postcode | number one pharmaceutical company november 2009 | sanofi aventi | Internal medicine drug discovery sanofi-aventis 2009 bridgewater | sanofi aventis press release November 3 2009 | sanofi-aventis october 09 | . Search for more companies in Bridgewater Search for more companies in New Jersey This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for sanofi-aventis |
